% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • mtaotter mtaotter Apr 25, 2013 5:37 PM Flag

    Herceptin subcutaneous is not being reviewed by CHMP this month -- not on calendar.

    Kadacyla is being reviewed, which is a herceptin combination drug. That drug is very toxic and comes with a black box warning in the U.S. when it was passed by the FDA earlier this year.

    I think we are waiting on HYQvia European Commission confirmation of CHMP validation back in March. I think the Mab Thera competitor failure is probably too bad for patients but good for Roche and likely Halozyme.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
9.90-0.32(-3.13%)May 4 4:00 PMEDT